Fosamax Osteonecrosis of the Jaw Attorney: Understanding the Statute of Limitations in Illinois

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Specific Pharmaceutical Risks

The legacy of mass production in health information has long centered on broad, foundational topics such as breast cancer anatomy, heart disease risk factors, and infectious disease management. These general health and science themes provided a necessary baseline for public understanding, emphasizing prevention, early detection, and treatment pathways. However, as pharmaceutical manufacturing scaled to meet widespread demand, the focus necessarily narrows from population-level education to individual exposure scenarios. In this transition, the same principles of risk awareness and timely intervention apply, but the context shifts to specific therapeutic agents and their potential long-term consequences. Consider the case of bisphosphonate medications like Fosamax, which were mass-produced for osteoporosis management. While these drugs offered significant benefits for bone density, prolonged use has been associated with rare but serious adverse events, including osteonecrosis of the jaw. This condition, involving bone death in the mandible or maxilla, typically arises after dental procedures or chronic exposure. For individuals in Illinois who have taken Fosamax and subsequently developed jaw complications, understanding the statute of limitations for legal recourse becomes paramount. This pivot from general health literacy to occupational and pharmaceutical exposure underscores the need for precise, timely action within legal frameworks.

Fosamax and Osteonecrosis of the Jaw: Medical Evidence and Risk Factors

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms of ONJ after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The incidence of ONJ in patients taking bisphosphonates is rare (https://pubmed.ncbi.nlm.nih.gov/42046648/). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/). The incidence of atypical femoral fracture or ONJ was uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). From a medical perspective, the clinical presentation of ONJ typically involves exposed bone in the jaw that does not heal within eight weeks after identification by a healthcare provider. Diagnosis is based on clinical examination and imaging, such as panoramic radiographs or CT scans, to assess the extent of bone involvement. The mechanistic pathways linking bisphosphonates like Fosamax to ONJ are not fully understood but are thought to involve suppression of bone turnover, reduced blood supply to the jaw, and impaired healing after dental procedures. Bisphosphonates inhibit osteoclast activity, which can lead to decreased bone remodeling and increased susceptibility to infection and necrosis, particularly in areas of high mechanical stress or after trauma.

Legal Considerations: Statute of Limitations for Fosamax Lawsuits in Illinois

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning about ONJ in Section 5.4 (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This warning notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors. However, the warning does not specify a precise timeline for onset, which can vary widely. The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of these warnings may be evaluated in the context of whether they sufficiently alert patients and healthcare providers to the risk, especially given that ONJ can occur spontaneously or after dental procedures. For affected patients in Illinois, attorney-related considerations involve the statute of limitations for filing a lawsuit related to Fosamax and ONJ. In Illinois, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. This means that patients who have been diagnosed with ONJ after taking Fosamax must file a claim within two years of discovering the link between their injury and the medication. The timeline between exposure to Fosamax and documented harm is critical, as ONJ can develop months or even years after starting the drug, and the statute of limitations may begin when the patient becomes aware of the potential connection. Patients should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances, including the date of diagnosis, the duration of Fosamax use, and any prior dental procedures that may have contributed to the condition. In summary, Fosamax is associated with a rare but serious risk of ONJ, with onset varying from days to months after starting the drug. The prescribing information includes warnings about this risk, but the adequacy of these warnings may be subject to legal scrutiny. Patients in Illinois who have developed ONJ after taking Fosamax should be aware of the two-year statute of limitations and seek legal advice promptly to preserve their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax lawsuits in Illinois?

In Illinois, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Fosamax, is generally two years from the date the injury was discovered or should have been discovered through reasonable diligence. This means patients diagnosed with osteonecrosis of the jaw (ONJ) after taking Fosamax must file a claim within two years of discovering the link between their injury and the medication.

What are the known risk factors for osteonecrosis of the jaw from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.